Literature DB >> 9028358

Malignant fibrous histiocytoma of bone. A clinicopathologic study of 81 patients.

J Nishida1, F H Sim, D E Wenger, K K Unni.   

Abstract

BACKGROUND: Malignant fibrous histiocytoma of bone, a relatively rare primary malignant neoplasm occurring in bone, is a distinct clinicopathologic entity formerly included in the category of osteosarcoma or fibrosarcoma. A series of patients treated at the Mayo Clinic for malignant fibrous histiocytoma of bone was studied to determine whether the prognosis for this disease is different from that of osteosarcoma and whether treatment should be different.
METHODS: The bone tumor files of the Mayo Clinic were reviewed for examples of malignant fibrous histiocytoma of bone. Clinical records and histologic slides were reviewed for 81 patients. Roentgenograms of 13 patients were available for review.
RESULTS: Patients with malignant fibrous histiocytoma of bone ranged in age from 6 to 81 years. The region most commonly affected was the knee. Seventy-eight percent of the lesions arose de novo and 22% in preexisting conditions. Histologically, most of the tumors were classified as the storiform pleomorphic type, although other histologic subtypes were identified. The prognosis depended on the types of surgical margins involved. Patients with wide or radical margins had a better prognosis than patients in whom the margins were contaminated. Some patients who received radiation therapy alone became long term survivors.
CONCLUSIONS: The overall prognosis for patients with malignant fibrous histiocytoma was not found to be significantly different from that described for patients with osteosarcoma in recent series. However, at least in this small series, some patients with malignant fibrous histiocytoma had a good response to radiation therapy. Osteosarcoma is generally considered radioresistant.

Entities:  

Mesh:

Year:  1997        PMID: 9028358

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Frequent expression of smooth muscle markers in malignant fibrous histiocytoma of bone.

Authors:  T Ueda; N Araki; M Mano; A Myoui; S Joyama; S Ishiguro; H Yamamura; K Takahashi; I Kudawara; H Yoshikawa
Journal:  J Clin Pathol       Date:  2002-11       Impact factor: 3.411

2.  Malignant fibrous histiocytoma and fibrosarcoma of bone: a re-assessment in the light of currently employed morphological, immunohistochemical and molecular approaches.

Authors:  Salvatore Romeo; Judith V M G Bovée; Herman M Kroon; Roberto Tirabosco; Cristina Natali; Lucia Zanatta; Raf Sciot; Fredrik Mertens; Nick Athanasou; Marco Alberghini; Karoly Szuhai; Pancras C W Hogendoorn; Angelo Paolo Dei Tos
Journal:  Virchows Arch       Date:  2012-09-22       Impact factor: 4.064

3.  MFH of bone and osteosarcoma show similar survival and chemosensitivity.

Authors:  Dae-Geun Jeon; Won Seok Song; Chang-Bae Kong; Jung Ryul Kim; Soo-Yong Lee
Journal:  Clin Orthop Relat Res       Date:  2010-06-18       Impact factor: 4.176

4.  Imaging findings, prevalence and outcome of de novo and secondary malignant fibrous histiocytoma of bone.

Authors:  Monica C Koplas; Robert A Lefkowitz; Thomas W Bauer; Michael J Joyce; Hakan Ilaslan; Jonathan Landa; Murali Sundaram
Journal:  Skeletal Radiol       Date:  2009-11-20       Impact factor: 2.199

5.  Surgical technique: Tibia cortical strut autograft interposition arthrodesis after distal radius resection.

Authors:  Michiel A J van de Sande; Niels H W van Geldorp; P D Sander Dijkstra; Antonie H M Taminiau
Journal:  Clin Orthop Relat Res       Date:  2013-03       Impact factor: 4.176

6.  Clinicopathological characteristics and survival of malignant fibrous histiocytoma of the bone: A population-based study using the SEER database.

Authors:  Bo Liu; Hong Wei; Yan-Jun Ren; Debo Zou; Kaining Zhang; Qingwei Ma; Xing Xiao
Journal:  PLoS One       Date:  2020-06-03       Impact factor: 3.240

7.  Clinical epidemiology and treatment outcomes of spindle cell non-osteogenic bone sarcomas - A nationwide population-based study.

Authors:  Kjetil Berner; Tom Børge Johannesen; Kirsten Sundby Hall; Øyvind S Bruland
Journal:  J Bone Oncol       Date:  2018-11-20       Impact factor: 4.072

8.  Clinical outcomes of non-osteogenic, non-Ewing soft-tissue sarcoma of bone--experience of the Toronto Sarcoma Program.

Authors:  Zachary W Veitch; Samir Fasih; Anthony M Griffin; Esmail M Al-Ezzi; Abha A Gupta; Peter C Ferguson; Jay S Wunder; Albiruni R Abdul Razak
Journal:  Cancer Med       Date:  2020-10-16       Impact factor: 4.452

9.  Clinical characteristics and prognostic factors of malignant fibrous histiocytoma of bone: a SEER population-based study.

Authors:  Lin Qi; Chao Tu; Xiaolei Ren; Ruiqi Chen; Lu Wan; Chenghao Zhang; Zhihong Li
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.